ReviewThorax2004
alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.
Review in Thorax, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 65 citations in OpenAlex.
- Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016Trial
- Article
- Protein quality control and aggregation in the endoplasmic reticulum: From basic to bedside.Frontiers in cell and developmental biology · 2023Review
- Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth.BMC medicine · 2022Article
- The Beneficial Effects of Antioxidants in Health And Diseases.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Review
- Calcium signalling in mammalian cell lines expressing wild type and mutant human α1-Antitrypsin.Scientific reports · 2019Article
- Article
- Advances in managing COPD related to αAllergy · 2018Review
- The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status.Journal of behavioral medicine · 2014Article
- The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis.Orphanet journal of rare diseases · 2013Review
- Adipose tissue-derived mesenchymal stem cell-based liver gene delivery.Journal of hepatology · 2011Article
- [Alpha1-antitrypsin deficiency in Austria: analysis of the Austrian Alpha1-international-registry database].Wiener klinische Wochenschrift · 2010Article
- Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Targeted treatment in COPD: a multi-system approach for a multi-system disease.International journal of chronic obstructive pulmonary disease · 2009Review
- Biological targets for therapeutic interventions in COPD: clinical potential.International journal of chronic obstructive pulmonary disease · 2006Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-1-antitrypsin (AAT) deficiency is a genetic condition that increases the risk of developing lung and liver disease, as well as other associated conditions. Most treatment of affected individuals is not specifically directed at AAT deficiency but focuses on the resultant disease state. The only currently available specific therapeutic agent-namely, intravenous augmentation with plasma derived AAT protein-is marketed in a limited number of countries. Treatments aimed at correcting the underlying genetic abnormality, supplementing or modifying the gene product, and halting or reversing organ injury are now beginning to emerge. These innovative approaches may prove effective at modifying or eliminating diseases association with AAT deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.